Curis, Inc.
61 Moulton Street
Cambridge
Massachusetts
02138
Tel: 617-876-0086
Fax: 617-876-0866
Website: http://www.curis.com/
507 articles about Curis, Inc.
-
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
8/18/2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the TakeAim Lymphoma Phase 1/2 study of emavusertib after reviewing the comprehensive data package submitted by Curis.
-
Curis Reports Second Quarter 2022 Financial Results and Business Update
8/4/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its financial results for the second quarter ended June 30, 2022 and provided business updates.
-
Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - July 29, 2022
7/29/2022
Curis, Inc. announced that on July 22, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of an inducement stock option to purchase a total of 540,000 shares of Curis common stock to a new employee, with a grant date of July 26, 2022, which is the employee's date of hire.
-
Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022
7/28/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that the Company will release its second quarter 2022 financial results on Thursday, August 4, 2022, after the close of U.S. markets.
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 07, 2022
7/7/2022
Curis, Inc. announced that on July 5, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 873,750 shares of Curis common stock to sixteen new employees, with a grant date of July 5, 2022.
-
Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress
6/10/2022
Curis scientists discover novel IRAK4 nuclear localization and describe potential use as a biomarker.
-
Legend Biotech and J&J, Adicet Bio, Curis and Immutep present optimistic early and mid-stage results at ASCO.
-
Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)
6/4/2022
Curis, Inc. announced the presentation of encouraging clinical data from both the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology Annual Meeting currently taking place in Chicago and online until June 7, 2022.
-
Curis to Present at 2022 Jefferies Global Healthcare Conference
6/2/2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will present a company overview at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 11:00 a.m.
-
Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)
5/12/2022
Curis, Inc. announced that multiple abstracts have been accepted for presentation at the upcoming European Hematology Association 2022 Hybrid Congress, which will be held virtually and in-person in Vienna on June 9-12, 2022.
-
Curis Reports First Quarter 2022 Financial Results and Business Update
5/5/2022
Curis, Inc. reported its financial results for the first quarter ended March 31, 2022 and provided business updates.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)
4/11/2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the Company's TakeAim Lymphoma study (NCT03328078).
-
Curis, a biotech company that develops treatments for cancer, has announced that the FDA has placed a partial clinical hold on its TakeAim lymphoma study.
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 07, 2022
4/7/2022
Curis, Inc. announced that on April 1, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 380,850 shares of Curis common stock to seven new employees, with a grant date of April 1, 2022.
-
Curis to Present at 21st Annual Needham Virtual Healthcare Conference
4/5/2022
Curis, Inc. today announced that James Dentzer , President and Chief Executive Officer of Curis, will present a company overview at the 21st Annual Needham Virtual Healthcare Conference.
-
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)
4/4/2022
Curis, Inc. announced that the U.S. Food and Drug Administration has placed a partial clinical hold on the Company's TakeAim Leukemia Phase 1/2a study.
-
Curis Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers
3/7/2022
Curis, Inc. (NASDAQ: CRIS), today announced that a manuscript has been published in the peer-reviewed journal Gastroenterology, authored by Curis collaborators at Washington University School of Medicine in St. Louis, on the role of IRAK4 in pancreatic ductal adenocarcinoma (PDAC) and the preclinical efficacy of emavusertib (CA-4948).
-
Curis Reports Fourth Quarter and Year End 2021 Financial Results
2/24/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its financial results for the fourth quarter ended December 31, 2021.
-
Curis to Release Fourth Quarter 2021 Financial Results and Hold Conference Call on February 24, 2022
2/17/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that the Company will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, after the close of U.S. markets.